Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCR-MYC in hepatocellular carcinoma
NCT02314052Phase 2Terminated
- Sponsor
- Novo Nordisk
- Start
- Jan 2015
- Primary completion
- Oct 2016
- Modality
- Antisense DNA, Lipid-based Nanoparticles, Conjugated siRNA
- Countries
- 3
01
Overview
A Phase 2 trial of DCR-MYC in hepatocellular carcinoma (HCC), sponsored by Novo Nordisk. Started Jan 2015; status: terminated.
02
Drugs
DCR-MYC
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02314052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02314052.